BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
TZID:Asia/Dubai
BEGIN:STANDARD
TZOFFSETFROM:+0400
TZOFFSETTO:+0400
TZNAME:+04
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20251007T200000
DTEND;TZID=UTC:20251007T210000
DTSTAMP:20260411T101518
CREATED:20250903T132214Z
LAST-MODIFIED:20250903T154639Z
UID:3073-1759867200-1759870800@clinicaltmssociety.org
SUMMARY:The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings\, Lessons Learned\, Future Directions
DESCRIPTION:> >Register Now <<\nSpeaker: Scott T. Aaronson\, MD\nThe RECOVER study is a large randomized sham controlled study of vagus nerve stimulation in markedly treatment resistant depression involving 1000 participants. The first papers for the unipolar cohort have been published and submitted to the Centers for Medicare and Medicaid for re-consideration for coverage. This presentation will review the extensive database\, the important lessons learned about studying severely treatment resistant depression and anticipate possible future availability of this novel therapy. \nKey learning objectives include:\n\nIdentify how to improve assessment of patient outcomes in severely treatment resistant depression.\nRecognize patient presentations with increased likelihood of benefit from vagus nerve stimulation.\nDescribe the proposed mechanism of action for vagus nerve stimulation in treating depression.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne CME credit is available.  CE Language \n*Registered attendees will receive access to the on-demand video recording by Friday\, October 10\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - October 7\, 2025 at 8:00pm ET | 5:00pm PT\nUK- October 8\, 2025 at 1:00am BST\nAustralia- October 8\, 2025 at 10:00am AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nScott T. Aaronson\, MD\nDr. Scott Aaronson is a thought leader in the areas of biological psychiatry\, diagnosis\, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine\, distinguished life fellow of the American Psychiatric Association\, and is a fellow of the American College of Psychiatrists\, the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr. Aaronson also serves on the board of the American Society for Clinical Psychopharmacology. He graduated with honors from Harvard Medical School and completed his psychiatric residency at McLean Hospital.\nDr. Aaronson is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. He has been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders\, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS)\, Vagus Nerve Stimulation (VNS) and psychedelics in the treatment of severe refractory mood disorders. His paper on a five year observational study of VNS in treatment resistant depression published in 2017 in the American Journal of Psychiatry led to the Centers for Medicare and Medicaid supporting a randomized clinical trial of VNS in unipolar and bipolar depression through their Coverage with Evidence Development Program. He is on the committee that developed this study and is now in the process of publishing the results from the unipolar arm in a series of articles.
URL:https://clinicaltmssociety.org/event/the-recover-trial-of-vagus-nerve-stimulation-in-markedly-treatment-resistant-depression-critical-findings-lessons-learned-future-directions/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2025/09/Events-Featured-Images-3.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20251202T200000
DTEND;TZID=UTC:20251202T210000
DTSTAMP:20260411T101518
CREATED:20251030T165119Z
LAST-MODIFIED:20251114T153619Z
UID:3226-1764705600-1764709200@clinicaltmssociety.org
SUMMARY:First Principles of TMS Induced Synaptic Plasticity and Potential Impact on Clinical Outcomes
DESCRIPTION:> >Register Now <<\nSpeaker: Alex McGirr\, MD\, PhD\, FRCPC\nTranscranial magnetic stimulation is delivered in patterns of pulses that are informed by pre-clinical electrophysiology to induce changes at the level of the synapse. Our delivery of this treatment is agnostic to two major confounds that influence the ability of synaptic weights to change in response to stimulation:\na) disease processes limiting plasticity\nb) concurrent pharmacology\nThis grand rounds will review clinically relevant implications of these\, and the emerging space using pharmacological adjuvants to enhance the effects of stimulation and its relation to clinical outcomes. \nKey learning objectives include:\n\nExplain the mechanisms of transcranial magnetic stimulation (TMS)\, inclucing how pulse patterns influence synaptic plasticity and the role of electrophysiological principles.\nIdentify factors that affect synaptic responsiveness to TMS\, such as disease-related limitations in plasticity and the impact of concurrent pharmacological treatments.\nDiscuss the clinical implications of combining TMS with pharmacological adjuvants\, including how these interactions can enhance stimulation effects and influence clinical outcomes.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, December 5\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - December 2\, 2025 at 8:00pm ET | 5:00pm PT\nUK- December 3\, 2025 at 1:00am GMT\nAustralia- December 3\, 2025 at 12:00pm AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nAlexander McGirr\, MD\, PhD\, FRCPC\nDr. Alexander McGirr is a psychiatrist and clinician scientist at the University of Calgary\, Canada. He trained across major Canadian institutions\, including\nMcGill University (undergraduate and masters of neuroscience)\, the University of Toronto (MD)\, and the University of British Columbia (psychiatry residency\nand PhD neuroscience). His clinical work and research focuses on mood disorders\, circuit dissection\, and non-invasive neurostimulation as both a means\nof probing the brain and inducing changes in neural circuits underlying pathology. Although his research program includes both basic science and\nclinical arms\, the focus of this ground rounds will be clinical.
URL:https://clinicaltmssociety.org/event/first-principles-of-tms-induced-synaptic-plasticity-and-potential-impact-on-clinical-outcomes/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/10/Events-Featured-Images-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260106T200000
DTEND;TZID=UTC:20260106T210000
DTSTAMP:20260411T101518
CREATED:20251203T171225Z
LAST-MODIFIED:20251211T164857Z
UID:3445-1767729600-1767733200@clinicaltmssociety.org
SUMMARY:Single-Day Regimens for TMS: Recent Progress and Open Questions *Free Session*
DESCRIPTION:Kick off the year with complimentary Grand Rounds!\n> >Register Now <<\nSpeaker: Jonathan Downar\, MD\, PhD\, FRCPC\nImproving access to TMS is a priority for practitioners and patients alike. Multi-day treatment protocols pose a significant logistical barrier to access for many patients\, especially those in remote areas. \nRecently\, proof-of-concept studies have begun to investigate the effectiveness of single-day TMS regimens. Here we review the development of single-day TMS protocols\, along with relevant studies on potential mechanisms. We consider new data on the outcomes of single-day TMS in various applications. We examine possible refinements of the approach to improve practicality\, tolerability\, and effectiveness. We consider important outstanding questions requiring future research on this novel but potentially quite impactful approach to TMS treatment. \nKey learning objectives include:\n\nReview rationale\, mechanisms\, and history of development of single-day TMS protocols.\nReview recent progress in refining single-day TMS protocols and comparative outcomes vs. conventional once-daily protocols.\nReview outstanding questions facing future developments and refinement of single-day TMS protocols.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, January 9\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - January 6\, 2026 at 8:00pm ET | 5:00pm PT\nUK- January 7\, 2026 at 1:00am GMT\nAustralia- January 7\, 2026 at 12:00pm AEDT \nCost: \nMember: FREE\nTrainee Member: FREE\nNon-Member: FREE \n*CME not available for this session. \n> >Register Now <<\nAbout the Speaker \n \nJonathan Downar\, MD\, PhD\, FRCPC \nDr Jonathan Downar is an Adjunct Professor in the Department of Psychiatry and Institute of Medical Science at the University of Toronto. He holds a clinical appointment at the Centre for Addiction and Mental Health in Toronto. He holds a PhD in functional neuroimaging from the University of Toronto\, trained in medicine at the University of Calgary\, and completed his psychiatry residency at the University of Toronto. \nDr Downar has published over 180 peer-reviewed articles on TMS and brain imaging\, in journals including Lancet\, JAMA Psychiatry\, Nature Medicine\, Nature Neuroscience\, and Brain Stimulation. He is the senior author of the THREE-D study\, a major Canadian TMS study published in Lancet in 2018 that demonstrated that TMS treatments could be reduced from 38 min sessions to 3 minute sessions with no loss of efficacy. He has also pioneered the use of novel TMS protocols including dorsomedial TMS and orbitofrontal TMS in depression and in other clinical disorders. \nHe is currently working to develop novel protocols that improve the practicality and economics of TMS\, with the goal of achieving cost parity with pharmacotherapy and universal access to this powerful treatment.
URL:https://clinicaltmssociety.org/event/single-day-regimens-for-tms-recent-progress-and-open-questions/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/12/Events-Featured-Images.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Dubai:20260203T200000
DTEND;TZID=Asia/Dubai:20260203T210000
DTSTAMP:20260411T101518
CREATED:20260107T174232Z
LAST-MODIFIED:20260107T174232Z
UID:3559-1770148800-1770152400@clinicaltmssociety.org
SUMMARY:TMS for Schizophrenia
DESCRIPTION:> >Register Now <<\nSpeaker: Roscoe Brady\, PhD\, MD\nIn this presentation we will review the use of TMS for treating symptoms of schizophrenia as well as its use as a research tool to understand schizophrenia pathophysiology. We will discuss symptoms such as medication refractory hallucinations\, negative symptoms\, and cognitive dysfunction. We will review different approaches including targets derived from both structural and functional neuroanatomy. Finally\, we will talk about future directions in treatment including the use of TMS for schizophrenia related comorbidity. \nKey learning objectives include:\n\nSummarize the history of TMS trials for medication resistant symptoms of schizophrenia.\nDescribe how TMS is used as a research tool for understanding schizophrenia pathology.\nDescribe future directions for TMS trials both for treating schizophrenia symptoms as well as schizophrenia related comorbidity.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, February 6\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - February 3\, 2026 at 8:00pm ET | 5:00pm PT\nUK- February 4\, 2026 at 1:00am GMT\nAustralia- February 4\, 2026 at 12:00pm AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nRoscoe Brady\nRoscoe Brady MD\, PhD is a board-certified psychiatrist and neuroscientist. He is the Vice-Chair for Research in the Department of Psychiatry at Beth Israel Deaconess Medical Center and an Associate Professor at Harvard Medical School. He is also the director of the Research Concentration in the Beth Israel Deaconess Medical Center Harvard Psychiatry Residency Training Program. He is the recipient of the Jonathan F. Borus Outstanding Early Educator Award and Stuart T. Hauser Mentorship Award from Harvard Medical School. His research focus is developing neuromodulation treatments for medication resistant symptoms of psychotic disorders. He is the Principal Investigator of multiple NIMH R01 funded clinical trials.
URL:https://clinicaltmssociety.org/event/tms-for-schizophrenia/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/01/Events-Featured-Images1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260303T200000
DTEND;TZID=UTC:20260303T210000
DTSTAMP:20260411T101518
CREATED:20260204T154404Z
LAST-MODIFIED:20260204T154526Z
UID:3684-1772568000-1772571600@clinicaltmssociety.org
SUMMARY:Accelerated TMS for Depression: Does Imaging Matter?
DESCRIPTION:> >Register Now <<\nSpeaker: Joseph J. Taylor\, MD\, PhD\nNeuroimaging is common in psychiatric research but rarely applied in psychiatric practice\, even for brain stimulation treatments like transcranial magnetic stimulation (TMS). Recently\, neuroimaging was used to target TMS during a condensed or “accelerated” treatment protocol. Known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)\, this intervention resulted in rapid and substantial antidepressant benefits. However\, it remains unclear if neuroimaging is necessary for the rapid and substantial antidepressant benefits of accelerated TMS. This question is important to answer because neuroimaging adds cost and complexity to TMS. Here\, we will present data from the first head-to-head trial of accelerated TMS with and without imaging guidance for treatment-resistant depression. \nKey learning objectives include:\n\nDescribe the development of accelerated TMS.\nOutline the five ways that the Cole et al protocol (branded SAINT) differs from conventional iTMS.\nSummarize the results of this trial comparing imaging-versus scalp-based targeting of accelerated TMS.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, March 6\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - March 3\, 2026 at 8:00pm ET | 5:00pm PT\nUK- March 4\, 2026 at 1:00am GMT\nAustralia- March 4\, 2026 at 12:00pm AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nJoseph J. Taylor\, MD\, PhD\nDr. Taylor is an Assistant Professor of Psychiatry at Harvard Medical School. At Brigham and Women’s Hospital\, he is the Medical Director of TMS and the Director of Clinical Trials in the Center for Brain Circuit Therapeutics\, the Director of the Interventional Psychiatry Research Program\, and the Associate Program Director and Research Track Co-Director of the Psychiatry Residency Program. Dr. Taylor’s has expertise in interventional psychiatry\, an emerging subspecialty in which procedural treatments are used for psychiatric illnesses that have not improved with routine psychotherapy and medications. Most of his research focuses on deriving and testing brain circuit targets for brain stimulation or neurosurgical ablation. Throughout his career\, Dr. Taylor has received funding from the Howard Hughes Medical Institute\, the National institutes of Health\, the Sidney R. Baer\, Jr. Foundation\, the Baszucki Group\, the Brain and Behavioral Research Foundation\, Mass General Brigham\, and Harvard Medical School.
URL:https://clinicaltmssociety.org/event/accelerated-tms-for-depression-does-imaging-matter/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/02/March-2026-GR-Thumb.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260307
DTEND;VALUE=DATE:20260309
DTSTAMP:20260411T101518
CREATED:20251029T214834Z
LAST-MODIFIED:20251205T204826Z
UID:3219-1772841600-1773014399@clinicaltmssociety.org
SUMMARY:CTMSS Training Singapore:  PULSES & Pain Academy
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/ctmss-training-singapore-pulses-pain-academy/
CATEGORIES:PULSES
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260407T200000
DTEND;TZID=UTC:20260407T210000
DTSTAMP:20260411T101518
CREATED:20260304T162017Z
LAST-MODIFIED:20260304T162017Z
UID:3928-1775592000-1775595600@clinicaltmssociety.org
SUMMARY:Marketing & Promotion of Off-Label Uses of Repetitive TMS Treatment (rTMS)
DESCRIPTION:> >Register Now <<\nSpeaker: Lindsay Oberman\, PhD\nThis talk will review the Pro’s and Cons of off-label use of TMS. Dr. Oberman will then discuss the FDA clearance process and what indications are considered “off-label”. Finally\, she will discuss the legal and ethical considerations for marketing and promoting off-label uses of TMS. \nKey learning objectives include:\n\nGain awareness of what indications are "on label" versus "off label."\nGain awareness of federal regulations regarding marketing and promotion of FDA cleared devices.\nGain understanding of ethical considerations regarding marketing and use of rTMS off-label.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, April 10\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - April 7\, 2026 at 8:00pm ET | 5:00pm PT\nUK- April 8\, 2026 at 1:00am BST\nAustralia- April 8\, 2026 at 10:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nLindsay Oberman\, PhD\nDr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time\, she has published over 80 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism\, mood disorders\, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation\, sensory processing\, social cognition\, and executive functioning across disorders. In doing so\, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.
URL:https://clinicaltmssociety.org/event/marketing-promotion-of-off-label-uses-of-repetitive-tms-treatment-rtms/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/03/April-2026-GR.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260505T200000
DTEND;TZID=UTC:20260505T210000
DTSTAMP:20260411T101518
CREATED:20260408T163027Z
LAST-MODIFIED:20260408T163027Z
UID:4127-1778011200-1778014800@clinicaltmssociety.org
SUMMARY:Combined Occipital and Trigeminal Afferent Stimulation for Depression: Findings from the Randomized Controlled Trial and the New ProLiv Home-Use Neuromodulation Device
DESCRIPTION:> >Register Now <<\nSpeaker: Linda Carpenter\, MD\nEarlier this year\, the FDA approved a novel home-use device for treatment of major depressive disorder in patients who have not responded to antidepressant medication. Available only with a prescription\, Proliv™Rx is a wearable\, at-home neurostimulation headset that uses non-invasive electrical pulses to stimulate the occipital and trigeminal nerves through surface electrodes. \nDr. Carpenter was the lead Principal Investigator for the large randomized controlled trial that generated efficacy and safety data for this device. She will present the data and describe how the ProLiv device will be used in future clinical practice. \nKey learning objectives include:\n\nEvaluate the clinical trial data supporting efficacy and safety of a new home-use device for treatment of Major Depressive Disorder (MDD).\nDescribe external combined occipital and trigeminal stimulation as a novel mechanism of action in the field of therapeutic neuromodulation.\nDiscuss how the ProLiv Rx device is incorporated into clinical care as an adjunct therapy for MDD.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, May 8\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - May 5\, 2026 at 8:00pm ET | 5:00pm PT\nUK- May 6\, 2026 at 1:00am BST\nAustralia- May 6\, 2026 at 10:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nLinda Carpenter\, MD\nDr. Carpenter has had nearly three decades of externally funded research focused on understanding biomarkers of early life stress and developing new treatments. She has expertise in clinical trials research involving pharmacotherapy and device-based neuromodulation treatments and has been PI on multiple industry- and NIH-funded randomized clinical trials\, evaluating the safety and efficacy of both drug- and device-based therapies for depression and anxiety disorders. She has also conducted studies examining various mechanisms of therapeutic action and biomarkers of risk for psychiatric disorders. \nFor the past two decades\, Dr. Carpenter's primary research focus has included therapeutic brain stimulation\, and she has led numerous studies examining the efficacy\, safety\, and mechanisms of VNS\, DBS\, tDCS\, TMS\, and other neuromodulation devices in clinical populations. \nDr. Carpenter recently led the multi-center investigation of Proliv\, a novel\, FDA-cleared home-use device that delivers electrical trigeminal/occipital nerve stimulation for depression\, and she is lead PI for a trial that uses fMRI-EEG-based neurofeedback for self-neuromodulation of a targeted depression circuit. \nFor the past 5 years Dr. Carpenter has also been developing methods for sustaining TMS antidepressant response over time with maintenance treatment and ecological momentary assessment. \nDr. Carpenter is the current Director of the CTMSS’s PULSES training course\, and she serves on multiple other CTMSS committees. \n 
URL:https://clinicaltmssociety.org/event/combined-occipital-and-trigeminal-afferent-stimulation-for-depression-findings-from-the-randomized-controlled-trial-and-the-new-proliv-home-use-neuromodulation-device/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/04/Events-Featured-Images2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260603
DTEND;VALUE=DATE:20260605
DTSTAMP:20260411T101518
CREATED:20251205T202828Z
LAST-MODIFIED:20251205T204613Z
UID:3474-1780444800-1780617599@clinicaltmssociety.org
SUMMARY:PULSES Boston
DESCRIPTION:Course Overview\nThis in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians\, engineers\, and researchers\, along with special guests. Attendees will receive current\, historical\, and practical knowledge for treating patients with TMS based on the best available evidence. \nThe Program Includes:\n\nA review of the clinical studies that serve as the foundation for treatment of TMS for depression\, as well as clinically applicable research and current important studies.\nFour lectures on the practical administration of TMS for patients\, including practice setup to patient dosing\, scheduling\, and management.\nA review of protocols for TMS: high frequency\, theta-burst\, low frequency\, bilateral\, alternative brain targets\, rescue treatment\, and maintenance treatment.\nA revised lecture on TMS risks and their prevention and management\, including seizure protocol review.\nHands-on training on coil location placement & motor threshold determination with multiple TMS devices.\nA review of promising indications beyond depression\, including\, obsessive compulsive disorder\, smoking cessation\, migraine\, post-traumatic stress disorder\, anxiety\, and pain.\nAn extended Q&A Panel with all PULSES faculty and special guests.\n\nMORE DETAILS COMING SOON...  Sign up for updates on when CTMSS opens PULSES registration...
URL:https://clinicaltmssociety.org/event/pulses-boston/
CATEGORIES:PULSES
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260604
DTEND;VALUE=DATE:20260605
DTSTAMP:20260411T101518
CREATED:20251230T150807Z
LAST-MODIFIED:20251230T150807Z
UID:3548-1780531200-1780617599@clinicaltmssociety.org
SUMMARY:Pain Academy Boston
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/pain-academy-boston/
CATEGORIES:Pain Academy
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260604
DTEND;VALUE=DATE:20260607
DTSTAMP:20260411T101518
CREATED:20251015T221100Z
LAST-MODIFIED:20251015T221100Z
UID:3190-1780531200-1780790399@clinicaltmssociety.org
SUMMARY:CTMSS 14th Annual Meeting
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/ctmss-14th-annual-meeting/
CATEGORIES:Annual Meetings
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/10/CTMSS-2026-Banner-Options-600-x-338-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261026
DTSTAMP:20260411T101518
CREATED:20251205T204708Z
LAST-MODIFIED:20251205T204708Z
UID:3499-1792713600-1792972799@clinicaltmssociety.org
SUMMARY:PULSES Providence
DESCRIPTION:Course Overview\nThis in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians\, engineers\, and researchers\, along with special guests. Attendees will receive current\, historical\, and practical knowledge for treating patients with TMS based on the best available evidence. \nThe Program Includes:\n\nA review of the clinical studies that serve as the foundation for treatment of TMS for depression\, as well as clinically applicable research and current important studies.\nFour lectures on the practical administration of TMS for patients\, including practice setup to patient dosing\, scheduling\, and management.\nA review of protocols for TMS: high frequency\, theta-burst\, low frequency\, bilateral\, alternative brain targets\, rescue treatment\, and maintenance treatment.\nA revised lecture on TMS risks and their prevention and management\, including seizure protocol review.\nHands-on training on coil location placement & motor threshold determination with multiple TMS devices.\nA review of promising indications beyond depression\, including\, obsessive compulsive disorder\, smoking cessation\, migraine\, post-traumatic stress disorder\, anxiety\, and pain.\nAn extended Q&A Panel with all PULSES faculty and special guests.\n\nMORE DETAILS COMING SOON...  Sign up for updates on when CTMSS opens PULSES registration...
URL:https://clinicaltmssociety.org/event/pulses-providence/
CATEGORIES:PULSES
END:VEVENT
END:VCALENDAR